![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, November 27, 2021 9:59:13 PM
Looks like ALL shareholders should have done the same as Dale ?
Yep. I sold in August before the crash. It got to the point where the risk was greater than the reward. When the NIH changed the primary endpoint of the ACTIV-5, that was a sign that the EUA was not coming in the short term.
But the gamble is different now. HGEN might fall to $4 with a UK rejection. Then it will rebound to $5 or $6 because of CAR-T. Long term, HGEN is worth more than $6 per share just from CAR-T alone. It is probably worth $60 per share from CAR-T alone. But the Covid investors skew it in the short term.
HGEN will still look promising for a US FDA EUA after a UK rejection. Lenz is still the most efficacious Covid therapeutic according to the data. Maybe the UK will authorize, but it is still a good investment if they reject. I was worried in August so I sold. I am no longer worried now at $6.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM